Cerecor Inc. Banner Image

Cerecor Inc. has reached its limit for free report views

Work for Cerecor Inc.? Upgrade Your Profile and unlock all your annual reports.

Cerecor Inc.

  • Ticker CERC
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Cerecor Inc. Logo Image
  • 11-50 Employees
  • Based in Rockville, Maryland
Cerecor is a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases. The company is advancing its clinical-stage pipeline of innovative therapies that address unmet patient needs within rare and orphan diseases. The company's rare disease pipeline includes CERC-801, CERC-802 and CERC-803 ("CERC-800 compoundsMore"), which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The U.S. Food and Drug Administration ("FDA") granted Rare Pediatric Disease Designation (“RPDD”) and Orphan Drug Designation ("ODD") to all three CERC-800 compounds, thus potentially qualifying the Company to receive a Priority Review Voucher ("PRV") upon approval of each new drug application ("NDA"). The company is also developing CERC-002, CERC-006 and CERC-007.
Cerecor Inc.

Most Recent Annual Report

Cerecor Inc. MOST RECENT 2019 Annual Report and Form 10K

Report Locked. Cerecor Inc. has reached its limit for free report views.

Older/Archived Annual Reports